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Abstract
Background: Febrile neutropenia (FN) after chemotherapy causes a high burden of morbidity and mortality. We aimed to
develop and validate a risk score to predict FN in the first cycle of chemotherapy.
Methods: We included patients with solid cancers and diffuse large B-cell lymphomas at Rigshospitalet, University of
Copenhagen, 2010-2016. Predictors of FN were analyzed using Poisson regression and random split-sampling.
Results: Among 6294 patients in the derivation cohort, 360 developed FN. Female sex, older age, cancer type, disease stage,
low albumin, elevated bilirubin, low creatinine clearance, infection before chemotherapy, and number of and type of
chemotherapy drugs predicted FN. Compared with those at low risk (n¼2520, 40.0%), the incidence rate ratio of developing
FN was 4.8 (95% confidence interval [CI] ¼ 2.9 to 8.1), 8.7 (95% CI ¼ 5.3 to 14.1) and 24.0 (95% CI ¼ 15.2 to 38.0) in the
intermediate (n¼1294, 20.6%), high (n¼1249, 19.8%) and very high (n¼1231, 19.6%) risk groups, respectively, corresponding
to a number needed to treat with granulocyte colony-stimulating factors to avoid one FN event in the first cycle of 284, 60, 34
and 14. The discriminatory ability (Harrell’s C-statistic ¼ 0.80, 95% CI ¼ 0.78 to 0.82) was similar in the validation cohort
(n¼3163) (0.79, 95% CI ¼ 0.75 to 0.82).
Conclusion: We developed and internally validated a risk score for FN in the first cycle of chemotherapy. The FENCE score is
available online and provides good differentiation of risk groups.
Febrile neutropenia (FN) is a common complication of chemo-
therapy associated with a high burden of morbidity and mor-
tality (1). Supportive care measures like treatment with
granulocyte colony-stimulating factors (G-CSF) and prophylac-
tic antibiotics can potentially lessen the burden of morbidity
and mortality if patients are correctly stratified according to
risk of FN (2–4). To minimize the incidence of FN and the asso-
ciated morbidity, clinical guidelines emphasize the benefit of
models that predict FN (5) but also recognize that there is no
“consensus nomogram” (6) and do not provide guidance on
how to weigh different risk factors when assessing the risk of
FN (5–7).
Currently, guidelines recommend prophylactic G-CSF if the
risk of FN is more than 20% for a chemotherapy regimen. If
the risk is less than 20%, prophylactic G-CSF is recommended in
the presence of risk factors. However, the guidelines rely on
data from randomized clinical trials, where FN rates are incon-
sistently reported (8,9). Further, FN rates are higher in observa-
tional studies (10) where the patients better resemble the
general cancer population.
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Moreover, it is not established how to assess the risk of FN
during an entire chemotherapy course. More than one-half of
the patients who develop FN do so in the first cycle (11), which
will often affect timing and dosing of chemotherapy and pro-
phylactic measures in the following cycles. We therefore found
it rational to predict FN during the first cycle (12–14).
Our aim was to develop a model to predict FN in the first cy-
cle of chemotherapy based on pre-therapy risk factors in con-
secutive treatment-naı¨ve patients with solid cancers or diffuse
large B-cell lymphomas (DLBCL). This personalized medicine
approach aims to provide clinicians with a tool that potentially
can be used to optimize the prescription of G-CSF, prophylactic
antibiotics, and intensity of patient monitoring to benefit
patients, healthcare systems, and society.
Methods
Study Design and Patient Selection
We assessed all initial visits of patients with solid cancers or
DLBCL at the Departments of Oncology and Haematology at
Rigshospitalet, University of Copenhagen, to perform a cohort
study of consecutive treatment-naı¨ve patients. The patients ini-
tiated cycle one of chemotherapy from January 1, 2010 to
November 30, 2016 with last follow-up on December 31, 2016.
To be eligible for the study, patients had to be treated with
standard first-line chemotherapy. We excluded patients with
temporary civil registration numbers, patients registered as ini-
tiating two different chemotherapy regimens simultaneously,
and patients with stem cell transplantations.
Baseline was defined as the first date of chemotherapy.
Patients were followed to the earlier of 1) FN, 2) death, 3) a new
cancer diagnosis, 4) change to a different chemotherapy regi-
men, or 5) end of follow-up (defined as the earlier of end of the
first cycle [Supplementary Methods, available online], loss to
follow-up, emigration, or December 31, 2016).
The study was approved by the Danish Data Protection
Agency (2012-58-0004; RH-2016-47; 04433) and the Danish
National Board of Health (3-3013-1060/1/).
Primary Outcome
FN was defined as a blood culture (regardless of whether it was
positive or negative) or death within three days of a neutrophil
count less than 0.5  109/L. Data on temperature measurements
were not routinely available before 2014 and were available for
only the Capital Region of Denmark; hence, a blood culture was
used as a measure of clinical suspicion of infection. If a leuko-
cyte count without neutrophil count was measured, a leukocyte
count less than or equal to 2.0  109/L was used as a proxy for
neutropenia less than 0.5  109/L (sensitivity 84%, specificity
94%, Supplementary Figure 1, available online).
In a sensitivity analysis, we used the more narrow definition
of FN: fever of at least 38 degrees Celsius within three days of a
neutrophil count less than 0.5  109/L.
Data Sources, Risk Factors, and Definitions
Data were retrieved from the Centre of Excellence for
Personalised Medicine for Infectious Complications in Immune
Deficiency data repository of electronic health records, contain-
ing nationwide data on biochemistry and microbiology
(Supplementary Methods, available online). Furthermore, we
used the Danish Lymphoma Registry (15), the National Patient
Registry (16), and the Civil Registration System (17). Patients
were linked across data sources using the 10-digit unique civil
registration number given to all Danish citizens.
We assessed a wide range of patient-, cancer-, and
treatment-related risk factors at baseline detailed in the
Supplementary Methods (available online). G-CSF and antibac-
terial prophylaxis were provided according to the guidelines
from the American Society of Clinical Oncology (6,18). All risk
factors were fitted as categorical variables with a category for
missing values if appropriate, and cutoffs were based on refer-
ence ranges (19) when possible and otherwise based on the lit-
erature (Supplementary Methods, available online).
Statistics
Patients were randomly split 2:1 into a derivation and a valida-
tion cohort, stratified on cancer type.
Model Derivation
Risk factors for FN were examined univariably using Poisson re-
gression, and factors with P less than .1 were included in a mul-
tivariable model. Subsequently, the factors not included (P .1)
were added in turn one at a time to assess whether their inclu-
sion improved model fit, either with a lower Akaike information
criterion or a P less than .1. As a sensitivity analysis, Cox pro-
portional hazard and Fine-Gray competing-risk regression mod-
els with death as a competing risk were investigated to test
model robustness.
Using the best fitting multivariable Poisson model, coefficients
were scaled by dividing all coefficients by the smallest coefficient
greater than 0.01 and rounding to the nearest whole number for
easily calculation. A FEbrile Neutropenia after ChEmotherapy
(FENCE) score per individual was calculated based on their mea-
sured risk factors and the assigned weight from their scaled coef-
ficients. Quintiles of the derived FENCE score were used to define
five categories of risk. Because the lowest two quintiles both had a
small absolute risk of FN, these were combined, leaving four risk
groups; low, intermediate, high, and very high.
Model Validation
The FENCE score was tested in the validation cohort, and the
discriminatory ability of the FENCE score model in the cohorts
was assessed and compared with Harrell’s C-statistic. FENCE
score performance was further evaluated by comparison of the
crude incidence rates and incidence rate ratios within FENCE
score groups, and incidence rate ratios associated with a 10-
point increase in the FENCE score.
Calculation of an Individual’s Risk of Developing FN
The risk of developing FN can be calculated using the formula:
Prob FN in cycle oneð Þ ¼
1 exp t exp b0 þ b1X1 þ b2X2 þ . . . bnXnð Þð Þð Þ;
where t denotes time (i.e., length of cycle one in days), Xn
denotes the risk factors, and bn denotes the parameter coeffi-
cients from the Poisson regression model. The FENCE score and
a tool to calculate risk of developing FN will be publicly available
at https://www.chip.dk/Tools-Standards/Clinical-risk-scores.
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Preventive Interventions
Prophylactic treatment with G-CSF and quinolones reduces the
incidence of FN by approximately 50% (20) and 25% (21), respec-
tively. We used these estimates for calculations of number
needed to treat to avoid one FN event during 21 days. Patients
treated with G-CSF were excluded when calculating numbers
needed to treat for prophylactic G-CSF.
Sensitivity Analyses
To test the applicability of our definition of FN, we assessed the
performance of the FENCE score in three scenarios: 1) using the
narrow definition of FN (i.e., documented fever and neutrope-
nia) in the period 2014 to 2016, 2) taking into account only the
FN events that met the neutropenia criterion of the FN defini-
tion (i.e., not events with a leukocyte count lower than or equal
to 2.0  109/L and missing neutrophil count), and 3) excluding
the patients treated with G-CSF.
Results
We assessed 15 204 patients of whom 11 229 were eligible for
the study because they initiated a first cycle of standard first-
line chemotherapy. We excluded 251 patients with temporary
civil registration numbers, 418 patients who were registered as
initiating two different chemotherapy regimens at baseline, 5
patients with stem cell transplantations, and 3 patients who
were registered as dead at baseline. Finally, patients treated
with weekly cisplatin and concomitant radiotherapy (n¼ 1095)
developed FN with a different time kinetic than other patients,
only developing FN on days 30 to 40 after chemotherapy and
not in a cycle-dependent manner as shown in Supplementary
Figure 2 (available online). Hence, we excluded them.
We included 9457 patients with 24 types of solid cancers and
DLBCL treated with 83 different chemotherapy regimens. The
patients were randomly split into a derivation cohort (n¼ 6294)
and a validation cohort (n¼ 3163). The random-split method
provided a similar distribution of the risk factors
(Supplementary Table 1, available online).
Derivation Cohort
Of the 6294 patients with a median age of 64 years (interquartile
range [IQR] ¼ 55–71 years), 3056 (48.6%) were female (Table 1). The
most common cancer types were gastric (n¼ 866, 13.8%), colorectal
(n¼ 802, 12.7%), breast (n¼ 773, 12.3%), and non–small cell lung
cancer (n¼ 725, 11.5%). FN developed in 360/6294 (5.7%) patients.
Ninety-four (1.5%) patients died during follow-up and 11 of these
deaths met the FN definition. A total of 884 patients stopped che-
motherapy after the first cycle. In univariate analyses female sex,
older age, higher Charlson Comorbidity Index score, cancer type,
disease stage, abnormal baseline hemoglobin, lymphocyte, plate-
let, albumin, bilirubin, alkaline phosphatase, lactate dehydroge-
nase, estimated glomerular filtration rate, and C-reactive protein
counts, elevated neutrophil-to-lymphocyte ratio, infection before
baseline (a blood culture sample was used as a proxy for infection),
concurrent radiotherapy, treatment with three or four chemother-
apy drugs as compared with one, and treatment with taxanes,
vinca alkaloids, and prophylactic G-CSF were associated with an
increased risk of FN (Supplementary Table 2, available online).
In the multivariable analysis, factors associated with an in-
creased risk of FN were female sex; older than 65 years; cancer
Table 1. Characteristics of the patients in the derivation cohort
(n¼ 6294) who developed febrile neutropenia in the first cycle of
standard first-line chemotherapy and those who did not*
Developed FN Did not develop FN
Characteristic
No. or median
(% or IQR)
No. or median
(% or IQR)
All 360 (100) 5934 (100)
Sex
Male 162 (45.0) 3076 (51.8)
Female 198 (55.0) 2858 (48.2)
Age, y 66 (55 to 72) 64 (55 to 71)
Charlson Comorbidity Index 2 (2 to 3) 2 (2 to 3)
Cancer type
Gastric 36 (10.0) 830 (14.0)
Brain 3 (0.8) 522 (8.8)
Head and neck 7 (1.9) 32 (0.5)
Oesophageal 12 (3.3) 282 (4.8)
Breast 37 (10.3) 736 (12.4)
Mesothelioma 8 (2.2) 322 (5.4)
Non–small cell lung 46 (12.8) 679 (11.4)
Small-cell lung 47 (13.1) 184 (3.1)
Colorectal 3 (0.8) 799 (13.5)
Ovarian 48 (13.3) 336 (5.7)
Cervical/endometrial 2 (0.6) 142 (2.4)
Bladder 5 (1.4) 194 (3.3)
Prostate 18 (5.0) 157 (2.6)
Testicular 30 (8.3) 191 (3.2)
Neuroendocrine 16 (4.4) 151 (2.5)
Lymphoma (DLBCL) 32 (8.9) 222 (3.7)
Other 10 (2.8) 155 (2.6)
Disease stage
Adjuvant/Ann Arbor I 49 (13.6) 1281 (21.6)
Neoadjuvant or concomitant/
Ann Arbor II
56 (15.6) 1615 (27.2)
Locally advanced or dissemi-
nated/Ann Arbor IIIþ
255 (70.8) 3038 (51.2)
Radiotherapy
No previous radiotherapy 320 (88.9) 5330 (89.8)
Initiated 0–30 days before
chemotherapy
15 (4.2) 137 (2.3)
Initiated 30–365 days before
chemotherapy
10 (2.8) 254 (4.3)
Initiated >365 days before
chemotherapy
15 (4.2) 213 (3.6)
Number of chemotherapy
drugs
1 120 (33.3) 1769 (29.8)
2 138 (38.3) 3170 (53.4)
3 94 (26.1) 934 (15.7)
4 8 (2.2) 61 (1.0)
Chemotherapy
Platinums 257 (71.4) 4011 (67.6)
Non-platinum alkylating
agents
73 (20.3) 1458 (24.6)
Taxanes 109 (30.3) 892 (15.0)
Topoisomerase inhibitors 121 (33.6) 1888 (31.8)
Antimetabolites 74 (20.6) 2052 (34.6)
Vinca alkaloids 44 (12.2) 390 (6.6)
Other chemotherapy 24 (6.7) 394 (6.6)
Prophylactic G-CSF 32 (8.9) 209 (3.5)
*FN ¼ febrile neutropenia; DLBCL ¼ diffuse large B-cell lymphomas; G-CSF ¼
granulocyte colony-stimulating factors; IQR ¼ interquartile range.
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Table 2. Multivariable model for the FENCE score for febrile neutropenia in the derivation cohort (n¼ 6294)
FENCE score model
Characteristic FN/total
Adjusted incidence
rate ratio (IRR)
Exact
coefficient
Coefficient to
use in FENCE
score calculation*
Example
patient
Intercept† 7.561
Sex
Male 162/3238 1 0 0 0
Female 198/3056 1.39 (1.06 to 1.81) 0.327 8
Age, y
<65 164/3250 1 0 0
65–74 143/2181 1.42 (1.09 to 1.85) 0.351 9 9
75 53/863 1.17 (0.80 to 1.70) 0.154 4
Cancer type
Gastric 36/866 1 0 0
Brain 3/525 0.41 (0.03 to 5.11) 0.891 22
Head and neck 7/39 7.95 (3.19 to 19.79) 2.073 52
Oesophageal 12/294 6.33 (1.91 to 20.93) 1.845 46
Breast 37/773 3.58 (0.29 to 44.74) 1.276 32
Mesothelioma 8/330 2.99 (0.87 to 10.25) 1.096 28
Non–small-cell lung 46/725 6.49 (2.03 to 20.70) 1.870 47
Small-cell lung 47/231 20.37 (6.81 to 60.90) 3.014 75
Colorectal 3/802 0.41 (0.09 to 1.84) 0.897 23
Ovarian 48/384 3.05 (1.11 to 8.43) 1.116 28
Cervical/endometrial 2/144 0.27 (0.05 to 1.49) 1.299 33
Bladder 5/199 3.18 (0.83 to 12.23) 1.156 29
Prostate 18/175 1.28 (0.38 to 4.30) 0.244 6 6
Testicular 30/221 30.16 (9.78 to 93.07) 3.407 85
Neuroendocrine 16/167 8.93 (2.66 to 29.95) 2.189 55
Lymphoma (DLBCL) 32/254 1.32 (0.18 to 9.59) 0.281 7
Other 10/165 1.49 (0.53 to 4.20) 0.398 10
Disease stage
Adjuvant/Ann Arbor I 49/1330 1 0 0
Neoadjuvant or concomitant/Ann Arbor II 56/1671 0.65 (0.34 to 1.27) 0.426 11
Locally advanced or disseminated/Ann Arbor
IIIþ
255/3293 1.31 (0.70 to 2.43) 0.267 7 7
Albumin‡,§
<Normal 140/1554 1.51 (1.18 to 1.94) 0.413 10 10
Normal 167/3505 1 0 0
>Normal 9/217 0.75 (0.38 to 1.48) 0.284 7
Missing 44/1018 0.90 (0.54 to 1.51) 0.104 3
Bilirubin‡
<5 mmol/L 81/1253 1.04 (0.80 to 1.34) 0.035 1
5–25 mmol/L 264/4883 1 0 0 0
>25 mmol/L 14/78 1.99 (1.13 to 3.50) 0.687 17
Missing 1/80 0.31 (0.02 to 4.41) 1.174 29
Estimated glomerular filtration rate (CKD-EPI) ‡
60 mL/min 45/487 1.65 (1.14 to 2.39) 0.502 13
60–90 mL/min 143/2602 1.19 (0.92 to 1.52) 0.170 4 4
90 mL/min 171/3161 1 0 0
Missing 1/44 2.11 (0.15 to 29.93) 0.747 19
C-reactive protein‡
<10 mg/L 92/1592 1 0 0 0
10 mg/L 184/2490 1.07 (0.82 to 1.41) 0.072 2
Missing 84/2212 0.70 (0.50 to 0.98) 0.362 9
Infection before chemotherapy‡,k
No 290/5557 1 0 0
Yes 70/737 1.51 (1.13 to 2.00) 0.409 10 10
Number of chemotherapy drugs
1 120/1889 1 0 0 0
2 138/3308 1.46 (0.43 to 4.92) 0.376 10
3 94/1028 6.59 (0.83 to 52.25) 1.886 47
4 8/69 9.18 (0.65 to 129.47) 2.217 56
(continued)
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type; disease stage; low albumin; elevated bilirubin; low esti-
mated glomerular filtration rate; infection before baseline;
treatment with two, three, or four chemotherapy drugs
compared with one; and receiving taxane chemotherapy
(Table 2). Most patients treated with G-CSF had either testicular
cancer or DLBCL (181/241, 75%), which caused collinearity for G-
CSF and cancer type. Therefore, we could not include G-CSF in
the model. Cox and Fine-Gray regression showed similar results
(results not shown).
A bilirubin level below normal yielded the smallest coeffi-
cient greater than 0.01 and was used to scale the other coeffi-
cients listed in Table 2. Kaplan-Meier plots of FN according to
risk groups are shown in Figure 1. Compared with those at low
risk (n¼ 2520, 40.0%), the incidence rate ratio of developing FN
was 4.8 (95% confidence interval [CI] ¼ 2.9 to 8.1), 8.7 (95% CI ¼
5.3 to 14.1), and 24.0 (95% CI ¼ 15.2 to 38.0) in the intermediate
(n¼ 1294, 20.6%), high (n¼ 1249, 19.8%), and very high (n¼ 1231,
19.6%) risk groups. The discriminatory ability was good with a
Harrell’s C-statistic of 0.80 (95% CI ¼ 0.78 to 0.82).
Validation Cohort
FN developed in 156/3163 (4.9%) patients. The FENCE score model
showed similar discriminatory ability as assessed by Harrell’s C-
statistic in the validation cohort (0.79, 95% CI ¼ 0.75 to 0.82)
(Table 3). Crude incidence rates and incidence rate ratios in-
creased across those with a low, intermediate, high, and very high
risk of FN, and the incidence rate ratios associated with a 10-point
increase in the FENCE score were similar in the two cohorts.
Calculation of an Individual’s FENCE Score and Risk of
Developing FN
Using Table 2, a 68-year-old (þ9) patient with disseminated (þ7)
prostate (þ6) cancer treated with docetaxel (þ31), with an albu-
min of 32 g/L (þ10), an eGFR of 80 mL/min (þ4) and an infection
(þ10) two months before chemotherapy would get 77 points and
be classified as very high risk. There was no contribution to the
FENCE score calculation from the remaining risk factors because
these were all in the reference groups. The risk of FN in cycle
one would be:
ProbðFN in cycle oneÞ¼1expð21ðdays in cycleÞðexpð7:561
interceptð Þþ0:351 age 6574yð Þþ0:267 disseminatedð Þþ0:244
prostateð Þþ1:241 docetaxelð Þþ 0:413 albumin< normalð Þþ0:170
ðestimated glomerular filtration rate 6090 mL=minÞþ0:409
ðinfection before chemotherapyÞÞÞÞ¼21:4%
Preventive Interventions
The number needed to treat to avoid one FN event during
21 days with G-CSF was 284, 60, 34, and 14 for the low, interme-
diate, high, and very high risk groups and 569, 120, 69, and 27
with prophylactic quinolones, respectively.
Sensitivity Analyses
In 2014 to 2016 there were 241 FN events in the two cohorts.
There were documented temperatures of 38.0 degrees Celsius or
Table 2. (continued)
FENCE score model
Characteristic FN/total
Adjusted incidence
rate ratio (IRR)
Exact
coefficient
Coefficient to
use in FENCE
score calculation*
Example
patient
Chemotherapy
Platinums
No 103/2026 1 0 0 0
Yes 257/4268 0.34 (0.09 to 1.28) 1.073 27
Non-platinum alkylating agents
No 287/4763 1 0 0 0
Yes 73/1531 0.94 (0.16 to 5.58) 0.065 2
Taxanes
No 251/5293 1 0 0
Yes 109/1001 3.46 (1.11 to 10.81) 1.241 31 31
Topoisomerase inhibitors
No 239/4285 1 0 0 0
Yes 121/2009 0.83 (0.24 to 2.87) 0.189 5
Antimetabolites
No 286/4168 1 0 0 0
Yes 74/2126 0.53 (0.14 to 2.03) 0.627 16
Vinca alkaloids
No 316/5860 1 0 0 0
Yes 44/434 0.85 (0.22 to 3.28) 0.163 4
Other chemotherapy
No 336/5876 1 0 0 0
Yes 24/418 0.14 (0.04 to 0.47) 1.982 50
*For each risk factor, only one level contributes to a patient’s risk of FN. For example, a 77-year-old patient gets 4 points for age. DLBCL ¼ diffuse large B-cell lympho-
mas; FN ¼ Febrile neutropenia; IRR ¼ incidence rate ratio.
†Needed if exact risk is to be calculated.
‡Assessed closest to and up to 90 days before baseline.
§The reference range differs based on sex and age; see Supplementary Methods (available online).
kA blood culture was used as a proxy for infection.
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higher in 179/202 (89%) patients with available temperature
measurements. The narrow definition of FN identified 156 FN
events, and 7 (4.5%) of these were not identified by the wider
definition of FN. Using the narrow definition, the incidence rate
was 0.17 (95% CI ¼ 0.14 to 0.19) and the incidence rate ratios in
the intermediate, high, and very high risk groups compared
with the low risk group were 8.1 (95% CI ¼ 3.0 to 21.3), 14.1 (95%
CI ¼ 5.5 to 36.1), and 39.1 (95% CI ¼ 15.9 to 96.0), respectively.
The discriminatory ability was similar with a Harrell’s C-statis-
tic of 0.81 (95% CI ¼ 0.78 to 0.84).
In the derivation cohort, 39/360 (10.8%) FN events were iden-
tified using the leukocytes criterion because neutrophils were
not measured. The discriminatory ability of the FENCE score
was similar in analyses counting only the FN events that met
the neutropenia criterion of the FN definition and in analyses
excluding the 241 (3.8%) patients treated with G-CSF in the first
cycle (results not shown).
Discussion
We have developed and internally validated a prediction model
for FN with good discriminatory ability in both the derivation
and validation cohorts. The study included more than 9000 con-
secutive treatment-naı¨ve patients with solid cancers and
DLBCL. We assessed risk factors that could potentially predict
FN based on previous studies (22) and used a nonbiased ap-
proach to define cutoffs for risk factors and a systematic ap-
proach to risk factor selection in our model. We used a diverse
population of patients with cancer representative for the gen-
eral cancer population and data readily available for the clini-
cian when initiating cycle one. This approach allowed us to
stratify patients according to risk of FN based on a simple risk
score. The FENCE score and the tool to calculate an individual’s
risk will be available online and can be incorporated into a clini-
cal system allowing for instant calculation of a risk estimate of
developing FN that can be used to guide prophylactic measures
such as G-CSF, antibiotics, and intensity of patient monitoring.
The change in risk of FN associated with an individual risk
factor can be exemplified by a patient with metastatic pancre-
atic cancer and no other risk factors for whom addition of a tax-
ane to gemcitabine is considered. The risk of FN in cycle one
would increase approximately 5-fold (incidence rate ratio  3.5
for taxane multiplied with incidence rate ratio  1.5 for two che-
motherapy drugs instead of one) from 1.1% to 5.6%.
Personalized medicine like this is only possible if it is based
on evidence of correct risk stratification from large cohort stud-
ies with high quality data. To transition to an era of precision
medicine (23) we need to implement risk score models in clini-
cal practice. Implementing even a simple electronic prescription
tool in high risk chemotherapy regimens with a risk of FN more
than 20% according to guidelines (ie, just reminding physicians
to prescribe G-CSF) has been shown to increase correct use of
prophylactic G-CSF and reduce the rate of FN (24). To further
guide clinicians, we plan to develop a risk score model for FN in
cycles two to six to allow for cycle-specific estimation of FN risk
as guidelines recommend (5,6).
The previous studies addressing this issue have generally in-
cluded fewer risk factors. The sufficiently powered studies often
rely on administrative data and claims databases (12,14,25) and
the few prospective studies (26–32) include fewer patients with
inherent power issues restricting the number of included risk
factors. The main exception is a prospective study by Lyman
et al. (13) that included 3638 patients with breast, lung, colorec-
tal, and ovarian cancer and lymphoma using split-sample
methods to develop and validate a prediction model for a com-
bined outcome of severe or FN in cycle one. Between previous
studies, there is little overlap on included risk factors (33).
The pathophysiological importance of the risk factors for de-
veloping FN is not established. Evidently, a myelosuppressive
chemotherapy regimen is required for FN to develop and
preexisting myelosuppression appears to exacerbate this
(13,14,22,33), but otherwise not much is known about the biolog-
ical mechanisms responsible for the risk factors’ associations
with FN. The poor biological understanding of the risk factors
and the small overlap in risk factors identified in this and other
studies (12,13) call for studies using a systems biology approach
to identify the biological pathways that lead to FN.
The major strength of this study was that we developed a risk
score that is easily calculable with an online tool from a common
set of risk factors available for patients with cancer that reliably
predicted FN in the first cycle of chemotherapy. Another advan-
tage was that we included unselected consecutive patients from
the general cancer population and used data generated through
routine care. Furthermore, we had access to nationwide data,
which ensures almost complete ascertainment of outcomes.
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Figure 1. Kaplan-Meier plots of febrile neutropenia after chemotherapy according to FENCE risk groups in the A) derivation (n¼ 6294) and B) validation (n¼3163)
cohorts.
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The inherent limitations of retrospective studies apply to
this study with a few additional limitations. We used collection
of a blood culture instead of a temperature measurement in our
definition of FN, which does not conform with clinical guide-
lines (6,7). Therefore, confirmation of the results, preferably in a
prospective cohort using a guideline-based definition, is
needed. However, for the FN events with available temperature
measurements, 89% had a documented fever and the discrimi-
natory ability of the FENCE score was similar when we only
analyzed FN events identified by the narrow definition (i.e.,
documented fever and neutropenia). Further, in our setting,
blood cultures are collected only when there is fever or clinical
suspicion of infection and not for routine surveillance in neu-
tropenic patients.
Collinearity with cancer type hindered inclusion of data on
prophylactic G-CSF in the multivariable model; however, only a
small subset of patients (241/6294, 3.8%) received prophylactic
G-CSF and when we excluded these patients the discriminatory
ability of the FENCE score was similar. Another limitation was
the lack of information on treatment with prophylactic antibiot-
ics. However, prophylactic antibiotics are rarely used because
they are not recommended except for patients anticipated to
have neutrophils lower than 0.1  109/L for more than seven
days (18). Immunomodulation by corticosteroids was also not
ascertainable. Despite these limitations, we were able to build a
model with good discriminatory ability in both cohorts, which
indicates that the variation in risk of FN is well captured by the
risk factors in the FENCE score.
In conclusion, we have developed a risk score that reliably
predicts the risk of FN in the first cycle of chemotherapy and
may be useful for personalizing patient management including
prescription of G-CSF and prophylactic antibiotics and guidance
for intensity of patient monitoring. Validation in external
cohorts and prospective validation of the FENCE score with as-
sessment of impact on rates of FN, mortality, and other patient-
relevant outcomes is needed before a general recommendation
of use of the FENCE score can be substantiated.
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